The estimated Net Worth of Gerald Lema is at least 425 千$ dollars as of 4 December 2017. Mr. Lema owns over 3,500 units of FibroGen Inc stock worth over 1,400$ and over the last 7 years he sold FGEN stock worth over 0$. In addition, he makes 423,772$ as Independent Director at FibroGen Inc.
Gerald has made over 1 trades of the FibroGen Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 3,500 units of FGEN stock worth 163,450$ on 4 December 2017.
The largest trade he's ever made was buying 3,500 units of FibroGen Inc stock on 4 December 2017 worth over 163,450$. On average, Gerald trades about 389 units every 0 days since 2017. As of 4 December 2017 he still owns at least 3,500 units of FibroGen Inc stock.
You can see the complete history of Mr. Lema stock trades at the bottom of the page.
Gerald Lema serves as Independent Director of the Company. Mr. Lema has served on our board of directors since September 2017. Mr. Lema has more than 28 years of pharmaceutical, diagnostics, healthcare, and consumer experience in Asia, Europe, the Middle East, Africa, the U.S., and Latin America. He currently serves as partner and representative director of Cylon Capital, a private investment group based in Tokyo that creates value for brands and technologies in the Japanese and Asia Pacific markets. Prior to Cylon Capital, Mr. Lema served as President of Asia Pacific at Baxter International from 2005 until 2015. He also served as President, Japan at Baxter International since April 2007. Before Baxter, Mr. Lema worked for 18 years at Abbott Laboratories where he held several positions of increasing responsibility in general management, strategy, and business development. His last position with Abbott was Corporate Vice President, Asia Pacific and Chairman, Abbott Japan, in Tokyo. Mr. Lema currently serves as a Director of Catalyst, a global nonprofit organization. He is co-author of Foreign Investment through Debt-Equity Swaps, and published in the MIT Sloan Management Review. Mr. Lema is a graduate of the Stanford University Executive Program, earned a Master of Business Administration from the Freeman School of Business at Tulane University, and has a Bachelor of Science, Engineering from Universidad del Valle, Colombia.
As the Independent Director of FibroGen Inc, the total compensation of Gerald Lema at FibroGen Inc is 423,772$. There are 14 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of 5,856,450$.
Gerald Lema is 59, he's been the Independent Director of FibroGen Inc since 2017. There are 10 older and 11 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
Gerald's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over 188,593,537$ worth of FibroGen Inc stock and bought 106,523 units worth 1,309,423$ . The most active insiders traders include Rory B Riggs、Thomas B Neff、Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 6,963$. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth 25,884$.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: